Regional Morning Notes

SECTOR UPDATE

REITs – Singapore

S-REITs Bi-Weekly Updates (16-31 Mar 22)

The domestic economy will receive an uplift from the easing of social distancing measures and the border reopening. Externally, the Russo-Ukrainian war creates heightened uncertainties and has pushed bond vields higher. We seek solace and support from S-REITs with resiliency. BUY ART (Target: S\$1.29), FCT (Target: S\$2.98), MCT (Target: S\$2.48) and MINT (Target: S\$3.72). Maintain OVERWEIGHT.

WHAT HAPPENED IN THE LAST TWO WEEKS

- FSTREI gained 5.0% in the past two weeks. Singapore has made a decisive shift to a new phase of living with COVID-19 as endemic. Group size for dining in at F&B establishments, including hawker centres and coffee shops, has increased from five to 10 fully vaccinated persons. Up to 75% of employees can return to the workplace, compared with the previous limit of 50%. Vaccinated Travel Framework has replaced the existing Vaccinated Travel Lane scheme. Fully vaccinated travellers and children aged 12 and below with COVID-19 test two days before departure will be able to enter Singapore starting 1 Apr 22. They no longer have to take an antigen rapid test (ART) within 24 hours of arrival. Travellers are not restricted to take only designated flights to enter Singapore quarantine-free. Quota on the number of daily arrivals was abolished.
- S-REITs rallied with optimism on the easing of COVID-19 restrictions. FSTREI gained by 5.0%, in line with the rally of 5.3% for FSSTI.
- **Top outperformer:** Hospitality REITs FHT, CDREIT, ART and FEHT gained 21.6%, 14.2%, 10.8% and 10.2% respectively. MAGIC gained 12.8% as Festival Walk benefits from the easing of social distancing measures in Hong Kong. US REITs MUST and UHU gained 8.9% and 8.3% respectively.
- **Top underperformer:** SASSR was stagnant due to the recent rise in COVID-19 infections in China. KREIT gained marginally by 0.8%, lagging other office plays, such as CICT (+5.1%) and SUN (+6.1%). PREIT, a defensive healthcare REIT, gained 1.1%. LREIT gained 1.1% amid its equity fund raising exercise.





Monday, 04 April 2022

OVERWEIGHT

(Maintained)

SEGMENTAL RATING


S-REITs	OVERWEIGHT	
Healthcare REITs	MARKET WEIGHT	
Hospitality REITs	OVERWEIGHT	
Industrial REITs	MARKET WEIGHT	
Office REITs	MARKET WEIGHT	
Retail REITs	OVERWEIGHT	
Source: UOB Kay Hian		

TOP S-REIT PICKS

Rec	Share Price (S\$)	Target Price (S\$)
BUY	1.13	1.29
BUY	2.44	2.98
BUY	1.89	2.48
BUY	2.69	3.72
	BUY BUY BUY	BUY 1.13 BUY 2.44 BUY 1.89

Source: UOB Kay Hian

FTSE ST ALL-SHARE REITS INDEX (FSTREI)



Source: UOB Kay Hian

ANALYST(S)

Jonathan Koh, CFA +65 6590 6620 jonathankoh@uobkayhian.com

TOP-20 S-REITS RANKED BY MARKET CAPITALISATION - VITAL STATISTICS

Source: UOB Kay Hian *Yield spread above 10-year Singapore government bond yield.

				Price	Target	Mkt Cap			Yield			read* (%)	Interest	Aggregate	WALE
Name	Ticker	Rec	Currency	31 Mar 22	Price	(US\$m)	Curr	Fwd	Curr	Fwd	Curr	Fwd	Coverage (x)	Leverage (%)	(years)
CapLand Int Com Trust	CICT SP	BUY	S\$	2.25	2.50	10,996	11.2	12.0	5.0	5.3	2.7	3.0	4.1	37.2	3.2
Ascendas REIT	AREIT SP	BUY	S\$	2.93	3.92	9,077	16.6	17.0	5.7	5.8	3.3	3.5	5.7	35.9	3.8
Mapletree Log	MLT SP	BUY	S\$	1.85	2.08	6,530	8.4	8.6	4.5	4.6	2.2	2.3	5.1	34.7	3.6
Mapletree Ind	MINT SP	BUY	S\$	2.69	3.72	5,314	14.2	15.0	5.3	5.6	3.0	3.2	6.4	39.9	4.2
Mapletree Comm	MCT SP	BUY	S\$	1.89	2.48	4,636	9.2	10.0	4.9	5.3	2.5	3.0	4.8	34.1	2.7
Frasers L&C Trust	FLT SP	BUY	S\$	1.46	1.79	3,977	7.7	7.8	5.2	5.3	2.9	3.0	8.4	34.3	4.8
Suntec REIT	SUN SP	BUY	S\$	1.75	1.74	3,704	9.2	9.1	5.3	5.2	2.9	2.9	2.6	43.7	3.3
Keppel REIT	KREIT SP	BUY	S\$	1.22	1.52	3,343	5.9	5.8	4.8	4.8	2.5	2.4	3.9	38.4	6.1
Mapletree NAC Trust	MAGIC SP	NR	S\$	1.23	n.a.	3,202	6.8	7.1	5.5	5.8	3.2	3.4	4.2	42.1	2.5
Frasers CT	FCT SP	BUY	S\$	2.44	2.98	3,064	12.9	12.9	5.3	5.3	3.0	3.0	5.8	34.5	1.8
Keppel DC REIT	KDCREIT SP	NR	S\$	2.28	n.a.	2,890	10.7	10.9	4.7	4.8	2.4	2.4	10.8	34.6	7.5
Ascott Trust	ART SP	BUY	S\$	1.13	1.29	2,738	5.4	6.0	4.8	5.3	2.5	3.0	3.7	37.1	n.a.
PLife REIT	PREIT SP	HOLD	S\$	4.70	4.72	2,099	14.8	15.2	3.1	3.2	0.8	0.9	21.5	35.4	17.3
SPH REIT	SPHREIT SP	NR	S\$	0.97	n.a.	2,006	5.5	5.6	5.7	5.8	3.3	3.4	7.3	30.3	2.7
OUE Comm REIT	OUECT SP	NR	S\$	0.42	n.a.	1,689	2.6	2.6	6.2	6.2	3.9	3.9	2.8	38.7	2.5
CapLand China Trust	CLCT SP	NR	S\$	1.21	n.a.	1,493	9.7	10.2	8.0	8.4	5.7	6.1	4.9	37.7	2.2
Cromwell REIT EUR	CERT SP	NR	€	2.28	n.a.	1,419	17.0	17.5	7.5	7.7	6.9	7.1	5.8	36.6	4.6
ESR REIT	EREIT SP	NR	S\$	0.43	n.a.	1,286	3.0	3.1	7.0	7.2	4.6	4.9	4.0	40.0	2.9
DigiCore REIT USD	DCREIT SP	BUY	US\$	1.11	1.32	1,249	4.3	5.2	3.9	4.7	1.5	2.3	12.2	35.1	7.0
Manulife REIT USD	MUST SP	BUY	US\$	0.675	0.8	1,191	5.6	5.8	8.3	8.6	6.0	6.3	3.4	42.8	5.1

* Yield spread above 10-year government bond yield. Source: Bloomberg, UOB Kay Hian

UOBKayHian

Regional Morning Notes

Monday, 04 April 2022

PEER COMPARISON

				Price	Target	Mkt Cap			d (%)		Debt to	Debt to	P/NAV
Name	Ticker	Rec	Curr	31 Mar 22	Price	(US\$m)	Hist	Curr	Fwd 1Y	Fwd 2Y	Equity (%)	Assets (%)	(x)
HEALTHCARE													
First REIT	FIRT SP	NR	S\$	0.31	n.a.	468	8.4	n.a.	n.a.	n.a.	59.6	33.6	0.85
PLife REIT	PREIT SP	HOLD	S\$	4.70	4.72	2,099	3.0	3.1	3.2	n.a.	57.7	35.3	1.98
<u>HOSPITALITY</u>													
Ascott Trust	ART SP	BUY	S\$	1.13	1.29	2,738	3.8	4.8	5.3	5.6	70.4	37.1	0.95
CDL HTrust	CDREIT SP	BUY	S\$	1.29	1.45	1,172	3.3	3.7	4.8	5.6	72.8	39.1	0.97
Far East HTrust	FEHT SP	BUY	S\$	0.65	0.76	949	4.0	4.4	5.9	6.1	57.6	38.3	0.78
Frasers HTrust	FHT SP	NR	S\$	0.535	n.a.	760	1.8	4.1	5.8	5.8	78.2	42.5	0.83
INDUSTRIAL													
AIMS APAC REIT	AAREIT SP	NR	S\$	1.39	n.a.	730	6.4	6.6	6.9	7.2	61.4	37.3	1.01
Ascendas REIT	AREIT SP	BUY	S\$	2.93	3.92	9,077	5.2	5.7	5.8	5.8	61.6	35.9	1.23
DigiCore REIT USD	DCRFIT SP	BUY	US\$	1.11	1.32	1,249	n.a.	3.9	4.7	4.7	36.9	24.1	1.32
ESR REIT	EREIT SP	NR	S\$	0.43	n.a.	1,286	6.9	7.0	7.2	7.7	74.5	40.0	1.09
Keppel DC REIT	KDCREIT SP	NR	S\$	2.28	n.a.	2,890	4.3	4.7	4.8	4.9	56.2	41.8	1.71
Mapletree Ind Trust	MINT SP	BUY	S\$	2.69	3.72	5,314	4.7	5.3	5.6	5.8	62.2	39.9	1.50
Mapletree Log Trust	MLT SP	BUY	S\$	1.85	2.08	6,530	4.5	4.5	4.6	4.7	64.0	34.7	1.35
OFFICE	MET OF	501	54	1.00	2.00	0,000	1.0	1.0	1.0	1.7	01.0	01.7	1.00
Keppel REIT	KREIT SP	BUY	S\$	1.22	1.52	3,343	4.8	4.8	4.8	5.3	71.6	38.4	0.95
RETAIL	KKEIT SI	001	54	1.22	1.52	3,343	4.0	4.0	ч.0	0.0	71.0	30.4	0.75
Frasers CT	FCT SP	BUY	S\$	2.44	2.98	3,064	5.0	5.3	5.3	5.3	46.3	34.5	1.06
Lendlease REIT	LREIT SP	NR	S\$	0.78	2.90 n.a.	1.001	6.0	6.2	6.6	6.7	69.3	33.5	0.96
Mapletree NAC Trust	MAGIC SP	NR	S\$	1.23	n.a.	3,202	5.0	5.5	5.8	6.0	84.6	42.1	1.00
Sasseur REIT	SASSR SP	BUY	3\$ S\$	0.845	1.12	762	8.4	9.0	9.1	9.4	42.9	26.1	0.85
SPH REIT	SPHREIT SP	NR	3\$ S\$	0.845	n.a.	2,006	0.4 5.6	9.0 5.7	5.8	9.4 5.9	42.9 51.0	30.4	1.07
		NR	33 S\$			2,000	5.0 6.5	6.4	5.8 6.7	5.9 6.9			0.76
Starhill Global DIVERSIFIED	SGREIT SP	NK	23	0.61	n.a.	1,007	0.0	0.4	0.7	0.9	61.7	36.1	0.70
		ND	C	1 01		1 400	7.0	0.0	0.4	0.7	77.0	07.7	0.70
CapLand China Trust	CLCT SP	NR	S\$	1.21	n.a.	1,493	7.2	8.0	8.4	8.7	77.0	37.7	0.78
CapLand Int Comm Trust	CICT SP	BUY	S\$	2.25	2.50	10,996	4.6	5.0	5.3	5.5	63.2	37.2	1.09
Frasers L&C Trust	FLT SP	BUY	S\$	1.46	1.79	3,977	5.3	5.2	5.3	5.4	55.9	34.3	1.18
Mapletree Comm Trust	MCT SP	BUY	S\$	1.89	2.48	4,636	5.0	4.9	5.3	5.4	53.2	34.1	1.10
OUE Comm REIT	OUECT SP	NR	S\$	0.42	n.a.	1,689	6.2	6.2	6.2	3.1	72.2	38.7	0.73
Suntec REIT	SUN SP	BUY	S\$	1.75	1.74	3,704	5.0	5.3	5.2	5.4	81.7	43.7	0.83
INTERNATIONAL REITS													
Cromwell REIT EUR	CERT SP	NR	€	2.28	n.a.	1,419	7.4	7.5	7.7	7.9	65.6	36.6	0.91
Elite Comm REIT GBP	ELITE SP	NR	£	0.65	0.95	409	8.4	7.5	8.0	8.3	78.1	42.4	1.07
IREIT Global	IREIT SP	NR	S\$	0.63	n.a.	537	7.0	7.1	7.1	8.1	53.7	32.1	0.78
KepPacOak REIT USD	KORE SP	BUY	US\$	0.735	1.10	766	8.6	8.6	8.5	9.4	66.0	37.2	0.90
Manulife REIT USD	MUST SP	BUY	US\$	0.675	0.80	1,191	7.9	8.3	8.6	8.9	81.8	42.8	1.00
Prime US REIT USD	PRIME SP	NR	US\$	0.755	n.a.	886	9.0	9.3	9.5	9.5	63.9	37.9	0.89
Utd Hampshire REIT USD	UHU SP	BUY	US\$	0.65	0.97	363	9.4	10.1	9.7	9.7	65.1	39.0	0.87


Source: Bloomberg, UOB Kay Hian

TOP-10 OUTPERFORMERS AND TOP-10 UNDERPERFORMERS RANKED BY WEEKLY SHARE PRICE PERFORMANCE

TOP OUTPERFORMERS (%))						TOP UNDERPERFORMERS (%)						
NAME	2WK	1MTH	3MTH	6MTH	1Y	YTD	NAME	2WK	1MTH	3MTH	6MTH	1Y	YTD
Frasers HTrust	21.6	21.6	15.1	17.6	0.9	15.1	Sasseur REIT	0.0	0.0	0.0	-1.2	-5.1	0.0
CDL HTrust	14.2	13.2	10.3	24.0	4.0	10.3	Keppel REIT	0.8	6.1	8.0	15.1	0.0	8.0
Mapletree NAC Trust	12.8	13.9	10.8	27.5	16.0	10.8	PLife REIT	1.1	5.1	-8.4	1.1	15.2	-8.4
Ascott Trust	10.8	9.7	9.7	22.2	5.6	9.7	Lendlease REIT	1.1	-3.2	-10.7	-8.2	-0.8	-10.7
Far East HTrust	10.2	13.0	10.2	4.8	3.2	10.2	AIMS APAC REIT	1.5	3.0	-4.1	-3.5	7.8	-4.1
Manulife REIT USD	8.9	3.8	0.7	-3.6	-7.5	0.7	Elite Comm REIT GBP	2.4	5.7	-2.3	-3.0	-3.0	-2.3
Utd Hampshire REIT USD	8.3	4.0	-2.3	-3.7	-3.0	-2.3	ESR REIT	2.4	2.4	-10.4	-7.5	10.6	-10.4
Frasers CT	8.0	8.0	5.6	7.5	-0.8	5.6	SPH REIT	2.6	1.0	-3.0	3.2	10.9	-3.0
CapLand China Trust	7.1	6.1	1.7	-2.4	-11.7	1.7	Prime US REIT USD	2.7	-1.3	-9.6	-11.7	-12.2	-9.6
Starhill Global	6.1	1.7	-6.9	-2.4	8.9	-6.9	Frasers L&C Trust	2.8	4.3	-3.9	-3.9	0.7	-3.9


Source: Bloomberg, UOB Kay Hian

RANKING BY DISTRIBUTION YIELD (FORWARD)



Source: UOB Kay Hian

RANKING BY P/NAV (CURRENT)



Source: UOB Kay Hian

Regional Morning Notes

Monday, 04 April 2022

Disclosures/Disclaimers

This report is prepared by UOB Kay Hian Private Limited ("UOBKH"), which is a holder of a capital markets services licence and an exempt financial adviser in Singapore.

This report is provided for information only and is not an offer or a solicitation to deal in securities or to enter into any legal relations, nor an advice or a recommendation with respect to such securities.

This report is prepared for general circulation. It does not have regard to the specific investment objectives, financial situation and the particular needs of any recipient hereof. Advice should be sought from a financial adviser regarding the suitability of the investment product, taking into account the specific investment objectives, financial situation or particular needs of any person in receipt of the recommendation, before the person makes a commitment to purchase the investment product.

This report is confidential. This report may not be published, circulated, reproduced or distributed in whole or in part by any recipient of this report to any other person without the prior written consent of UOBKH. This report is not directed to or intended for distribution to or use by any person or any entity who is a citizen or resident of or located in any locality, state, country or any other jurisdiction as UOBKH may determine in its absolute discretion, where the distribution, publication, availability or use of this report would be contrary to applicable law or would subject UOBKH and its connected persons (as defined in the Financial Advisers Act, Chapter 110 of Singapore) to any registration, licensing or other requirements within such jurisdiction.

The information or views in the report ("Information") has been obtained or derived from sources believed by UOBKH to be reliable. However, UOBKH makes no representation as to the accuracy or completeness of such sources or the Information and UOBKH accepts no liability whatsoever for any loss or damage arising from the use of or reliance on the Information. UOBKH and its connected persons may have issued other reports expressing views different from the Information and all views expressed in all reports of UOBKH and its connected persons are subject to change without notice. UOBKH reserves the right to act upon or use the Information at any time, including before its publication herein.

Except as otherwise indicated below, (1) UOBKH, its connected persons and its officers, employees and representatives may, to the extent permitted by law, transact with, perform or provide broking, underwriting, corporate finance-related or other services for or solicit business from, the subject corporation(s) referred to in this report; (2) UOBKH, its connected persons and its officers, employees and representatives may also, to the extent permitted by law, transact with, perform or provide broking or other services for or solicit business from, other persons in respect of dealings in the securities referred to in this report or other investments related thereto; (3) the officers, employees and representatives of UOBKH may also serve on the board of directors or in trustee positions with the subject corporation(s) referred to in this report. (All of the foregoing is hereafter referred to as the "Subject Business"); and (4) UOBKH may otherwise have an interest (including a proprietary interest) in the subject corporation(s) referred to in this report.

As of the date of this report, no analyst responsible for any of the content in this report has any proprietary position or material interest in the securities of the corporation(s) which are referred to in the content they respectively author or are otherwise responsible for.

IMPORTANT DISCLOSURES FOR U.S. PERSONS

This research report was prepared by UOBKH, a company authorized, as noted above, to engage in securities activities in Singapore. UOBKH is not a registered broker-dealer in the United States and, therefore, is not subject to U.S. rules regarding the preparation of research reports and the independence of research analysts. This research report is provided for distribution by UOBKH (whether directly or through its US registered broker dealer affiliate named below) to "major U.S. institutional investors" in reliance on the exemption from registration provided by Rule 15a-6 of the U.S. Securities Exchange Act of 1934, as amended (the "Exchange Act"). All US persons that receive this document by way of distribution from or which they regard as being from UOBKH by their acceptance thereof represent and agree that they are a major institutional investor and understand the risks involved in executing transactions in securities.

Any U.S. recipient of this research report wishing to effect any transaction to buy or sell securities or related financial instruments based on the information provided in this research report should do so only through UOB Kay Hian (U.S.) Inc ("UOBKHUS"), a registered brokerdealer in the United States. Under no circumstances should any recipient of this research report effect any transaction to buy or sell securities or related financial instruments through UOBKH.

UOBKHUS accepts responsibility for the contents of this research report, subject to the terms set out below, to the extent that it is delivered to and intended to be received by a U.S. person other than a major U.S. institutional investor.

The analyst whose name appears in this research report is not registered or qualified as a research analyst with the Financial Industry Regulatory Authority ("FINRA") and may not be an associated person of UOBKHUS and, therefore, may not be subject to applicable restrictions under FINRA Rules on communications with a subject company, public appearances and trading securities held by a research analyst account.

UOBKayHian

Regional Morning Notes

Monday, 04 April 2022

Analyst Certification/Regulation AC

Each research analyst of UOBKH who produced this report hereby certifies that (1) the views expressed in this report accurately reflect his/her personal views about all of the subject corporation(s) and securities in this report; (2) the report was produced independently by him/her; (3) he/she does not carry out, whether for himself/herself or on behalf of UOBKH or any other person, any of the Subject Business involving any of the subject corporation(s) or securities referred to in this report; and (4) he/she has not received and will not receive any compensation that is directly or indirectly related or linked to the recommendations or views expressed in this report or to any sales, trading, dealing or corporate finance advisory services or transaction in respect of the securities in this report. However, the compensation received by each such research analyst is based upon various factors, including UOBKH's total revenues, a portion of which are generated from UOBKH's business of dealing in securities.

Reports are distributed in the respective countries by the respective entities and are subject to the additional restrictions listed in the following table.

General	This report is not intended for distribution, publication to or use by any person or entity who is a citizen or resident of or
	located in any country or jurisdiction where the distribution, publication or use of this report would be contrary to
Hong Kong	applicable law or regulation. This report is distributed in Hong Kong by UOB Kay Hian (Hong Kong) Limited ("UOBKHHK"), which is regulated by the
Hong Kong	Securities and Futures Commission of Hong Kong. Neither the analyst(s) preparing this report nor his associate, has
	trading and financial interest and relevant relationship specified under Para. 16.4 of Code of Conduct in the listed
	corporation covered in this report. UOBKHHK does not have financial interests and business relationship specified under Para. 16.5 of Code of Conduct with the listed corporation covered in this report. Where the report is distributed in Hong
	Kong and contains research analyses or reports from a foreign research house, please note:
	(i) recipients of the analyses or reports are to contact UOBKHHK (and not the relevant foreign research house) in Hong
	Kong in respect of any matters arising from, or in connection with, the analysis or report; and
	(ii) to the extent that the analyses or reports are delivered to and intended to be received by any person in Hong Kong who is not a professional investor, or institutional investor, UOBKHHK accepts legal responsibility for the contents of the
	analyses or reports only to the extent required by law.
Indonesia	This report is distributed in Indonesia by PT UOB Kay Hian Sekuritas, which is regulated by Financial Services Authority
	of Indonesia ("OJK"). Where the report is distributed in Indonesia and contains research analyses or reports from a
	foreign research house, please note recipients of the analyses or reports are to contact PT UOBKH (and not the relevant
	foreign research house) in Indonesia in respect of any matters arising from, or in connection with, the analysis or report.
Malaysia	Where the report is distributed in Malaysia and contains research analyses or reports from a foreign research house, the
	recipients of the analyses or reports are to contact UOBKHM (and not the relevant foreign research house) in Malaysia,
	at +603-21471988, in respect of any matters arising from, or in connection with, the analysis or report as UOBKHM is the
0:	registered person under CMSA to distribute any research analyses in Malaysia.
Singapore	This report is distributed in Singapore by UOB Kay Hian Private Limited ("UOBKH"), which is a holder of a capital
	markets services licence and an exempt financial adviser regulated by the Monetary Authority of Singapore.Where the report is distributed in Singapore and contains research analyses or reports from a foreign research house, please note:
	(i) recipients of the analyses or reports are to contact UOBKH (and not the relevant foreign research house) in Singapore
	in respect of any matters arising from, or in connection with, the analysis or report; and
	(ii) to the extent that the analyses or reports are delivered to and intended to be received by any person in Singapore
	who is not an accredited investor, expert investor or institutional investor, UOBKH accepts legal responsibility for the
	contents of the analyses or reports only to the extent required by law.
Thailand	This report is distributed in Thailand by UOB Kay Hian Securities (Thailand) Public Company Limited, which is regulated
	by the Securities and Exchange Commission of Thailand.
United	This report is being distributed in the UK by UOB Kay Hian (U.K.) Limited, which is an authorised person in the meaning
Kingdom	of the Financial Services and Markets Act and is regulated by The Financial Conduct Authority. Research distributed in
Ū	the UK is intended only for institutional clients.
United	This report cannot be distributed into the U.S. or to any U.S. person or entity except in compliance with applicable U.S.
States of	laws and regulations. It is being distributed in the U.S. by UOB Kay Hian (US) Inc, which accepts responsibility for its
America	contents. Any U.S. person or entity receiving this report and wishing to effect transactions in any securities referred to in
('U.S.')	the report should contact UOB Kay Hian (US) Inc. directly.

Copyright 2022, UOB Kay Hian Pte Ltd. All rights reserved.

http://research.uobkayhian.com

RCB Regn. No. 197000447W